

AMENDMENTS TO THE CLAIMS

1-13. (canceled)

14. (previously presented) A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding forkhead box O1A, wherein the compound is at least 70% complementary to said nucleic acid molecule, wherein the compound inhibits the expression of said nucleic acid molecule, and wherein the compound comprises the nucleobase sequence of SEQ ID NO: 172.

15. (currently amended) ~~A compound~~ An antisense oligonucleotide 8 to 80 nucleobases in length targeted to a the nucleic acid molecule of SEQ ID NO: 4 encoding forkhead box O1A, wherein the compound is at least ~~70~~ 75% complementary to said nucleic acid molecule, wherein the compound inhibits the expression of said nucleic acid molecule, and wherein the compound comprises at least 8 consecutive nucleobases of SEQ ID NO: 172.

16-18. (canceled)

19. (previously presented) A compound of claim 14 which is an antisense oligonucleotide.

20. (original) A compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

21. (original) A compound of claim 20 wherein the modified internucleoside linkage is a phosphorothioate linkage.

22. (original) A compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

23. (original) A compound of claim 22 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

24. (original) A compound of claim 19 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

25. (original) A compound of claim 24 wherein the modified nucleobase is a 5-methylcytosine.

26. (original) A compound of claim 19 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

27. (previously presented) A composition comprising the compound of claim 14 and a pharmaceutically acceptable carrier or diluent.

28. (original) A composition of claim 27 further comprising a colloidal dispersion system.
29. (original) A composition of claim 27 wherein the compound is an antisense oligonucleotide.
30. (withdrawn) A method of decreasing the expression of forkhead box O1A in cells or tissues comprising contacting the cells or tissues with a compound of claim 1 so that expression of forkhead box O1A is decreased.
31. (withdrawn) A method of claim of claim 30 wherein ghte tissues or cells is liver or fat tissue or cells.
32. (withdrawn) A method of treating an animal having a disease or condition associated with forkhead box O1A comprising administering to the animal a therapeutically or prophylactically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased.
33. (withdrawn) A method of claim 32 wherein the disease or condition is a hyperproliferative disorder.
34. (withdrawn) A method of claim 33 wherein the hyperproliferative disorder is cancer.
35. (withdrawn) A method of claim 34 wherein the cancer is rhabdomyosarcoma.
36. (withdrawn) A method of claim 32 wherein the disease or condition is diabetes.
37. (withdrawn) A method of claim 36 wherein the diabetes is type 2.
38. (canceled)
39. (withdrawn) A method of decreasing blood or plasma glucose in an animal comprising administering to the animal a therapeutically or prophylactically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased.
40. (withdrawn) A method of improving glucose tolerance in an animal comprising administering to the animal a therapeutically or prophylactically effective amount of a compound of claim 1 so that expression of forkhead box O1A is decreased.
41. (withdrawn) A method of normalizing insulin levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of a compound of claim 1 so that expression of forkhead O1A is decreased.
42. (currently amended) ~~A compound~~ An antisense oligonucleotide 15 to 30 nucleobases in length comprising at least 8 consecutive nucleobases of SEQ ID NO: 172 wherein the oligonucleotide is at least 75% complementary to the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A.
43. (canceled)

44. (currently amended) ~~A compound~~ An antisense oligonucleotide of claim 42 wherein the ~~compound~~ oligonucleotide is at least 80% complementary to a the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A.

45. (currently amended) ~~A compound~~ An antisense oligonucleotide of claim 42 wherein the ~~compound~~ oligonucleotide is at least 90% complementary to a the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A.

46. (currently amended) ~~A compound~~ An antisense oligonucleotide of claim 42 wherein the ~~compound~~ oligonucleotide is at least 95% complementary to a the nucleic acid molecule of SEQ ID NO 4 encoding forkhead box O1A.

47. (currently amended) ~~A compound~~ An antisense oligonucleotide of claim 42 wherein said ~~compound~~ oligonucleotide is 20 nucleobases in length.

48. (previously presented) A compound 20 nucleobases in length comprising the nucleobase sequence of SEQ ID NO: 172.

49. (previously presented) The compound of claim 48 further comprising at least one modified internucleoside linkage or at least one modified sugar moiety.

50. (previously presented) The compound of claim 48 further comprising at least one 2'-O-methoxyethyl sugar moiety.

51. (previously presented) The compound of claim 48 characterized by a ten deoxynucleotide gap flanked on its 5' and 3' ends with 5' 2'-O-methoxyethyl nucleotides.

52. (Currently Amended) The compound of claim 51 ~~wherein each internucleoside linkage is a~~ further comprising phosphorothioate linkages for each internucleoside linkage.

53. (Currently Amended) The compound of claim 51 ~~wherein each cytosine is a~~ further comprising a 5-methylcytosine for each cytosine.